YOLFTbeta
SkinBioTherapeutics PLC

SkinBioTherapeutics PLC

SBTX · LSE · Healthcare / Biotechnology

4.75GBX

Price History

Full chart

Market Stats

Open4.75
Day Range4.50 – 4.97
52-Week Range4.50 – 23.00
Volume73.32K
Market Cap12.31M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta0.08
50-Day Avg6.30
200-Day Avg7.54

About

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Driffield, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Rachel Lisa Parsonage
  • Employees41
  • HeadquartersUnit 75, Driffield, United Kingdom, YO25 9FQ, UK
  • Websitehttps://www.skinbiotherapeutics.com

Leadership

  • Ms. Rachel Lisa ParsonageCEO & Director · b. 1974
  • Ms. Anita SlaterInterim Chief Financial Officer
  • Ms. Vanessa RyderCustomer Service and Operations Manager
  • Ms. Vicky ChristieGroup Marketing Manager
  • Mr. Tom WaughmanManaging Director at Dermatonics
  • Mr. Tim WakeleyManaging Director at Bio-Tech Solutions
  • Ms. Melissa GreenwellGroup Financial Controller

Financials

Income Statement

Currency: GBP2016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue2.77K00-0074.76K132.06K1.21M4.64M
Growth (%)--100.00%-----+76.64%+815.51%+283.63%
Cost of Revenue0003.40K5.10K5.05K29.42K46.87K525.63K1.93M
Gross Profit2.77K00-3.40K-5.10K-5.05K45.34K85.19K683.04K2.71M
Gross Margin100.00%-----60.64%64.51%56.50%58.33%
Operating Expense6.97K673.00K941.00K1.36M1.61M1.49M3.03M3.08M3.59M3.53M
Operating Income-4.20K-673.00K-941.00K-1.36M-1.62M-1.49M-2.98M-3.00M-2.90M-826.79K
Operating Margin-151.72%------3988.83%-2271.26%-240.28%-17.83%
EBITDA-323-169.00K1-1.36M-1.61M-1.49M-2.95M-2.96M-2.72M-196.54K
EBITDA Margin-11.66%------3949.14%-2237.79%-225.14%-4.24%
Net Income-4.20K-646.00K-844.00K-1.15M-1.50M-1.43M-2.79M-2.84M-2.88M-696.25K
Net Income Margin-151.72%------3735.37%-2146.91%-237.88%-15.01%
R&D1.29K156.73K415.90K708.08K635.23K505.63K861.38K930.64K562.91K127.35K
R&D as % of Total Revenue46.66%-----1152.18%704.72%46.56%2.75%
Interest Expense015.54K00092610.13K8.89K51.40K91.98K
Interest Expense % of Total Revenue0.00%-----13.56%6.73%4.25%1.98%

Balance Sheet

Currency: GBP2016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets423.49K4.33M3.65M3.93M2.77M5.73M3.08M2.59M5.22M12.13M
Total Liabilities33.64K118.66K209.29K121.33K304.83K519.67K609.61K599.34K2.25M2.71M
Total Equity389.85K4.21M3.44M3.81M2.47M5.22M2.48M1.99M2.97M9.42M
Cash256.67K3.92M3.18M3.12M2.16M4.61M1.80M1.31M800.90K4.78M
Total Debt-----139.85K127.86K100.65K818.74K993.47K
Net Debt-256.67K-3.92M-3.18M-3.12M-2.16M-4.47M-1.68M-1.21M17.84K-3.79M

Cash Flow

Currency: GBP2016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow-1.17K-609.70K-667.75K-1.43M-892.14K-1.56M-2.67M-2.65M-2.73M-1.30M
Investing Cash Flow-136.21K-79.20K-72.26K-69.40K-73.67K-112.31K-96.81K-165.28K-2.30M-1.62M
Financing Cash Flow394.05K4.36M1.44M1.44M1.44M4.12M-35.12K2.32M4.51M6.90M
Capital Expenditure136.21K79.20K72.26K10.20K73.67K112.31K96.81K165.28K198.17K6.30K
Free Cash Flow-137.38K-688.90K-740.00K-1.44M-965.80K-1.67M-2.77M-2.81M-2.92M-1.30M
FCF to OCF11772.15%112.99%110.82%100.71%108.26%107.22%103.62%106.25%107.27%100.49%

Earnings

Report DateFeb 3, 2017Oct 5, 2017Feb 21, 2018Oct 25, 2018Feb 14, 2019Nov 26, 2019Mar 3, 2020Dec 4, 2020Mar 15, 2021Nov 30, 2021Mar 29, 2022Dec 15, 2022Mar 28, 2023Mar 26, 2025Dec 4, 2025
EPS Estimate---------------
EPS Actual0.000.000.000.000.000.00-0.01-0.010.00-0.01-0.01-0.01-0.010.000.00
Surprise---------------
Timing----------Pre-marketPre-marketPre-market--

Key Statistics & Ratios

Market Cap12.31M
Enterprise Value10.12M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.35
Price / Book1.54
EPS0.00
Book Value0.031
Revenue (TTM)5.23M
Gross Profit (TTM)3.19M
EBITDA-734.47K
Profit Margin-8.73%
Operating Margin-20.95%
Return on Equity-7.32%
Return on Assets-8.10%
Shares Outstanding259.17M
Shares Float116.00M
Beta0.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%